Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, WuXi AppTec, Asymchem Laboratories, Hangzhou Tigermed Consulting, and APT Medical [6][32] - The report also maintains an "Outperform" rating for H-Shares including PATEO, Hansoh Pharmaceutical Group, Innovent Biologics, WuXi XDC Cayman, Luye Pharma Group, and BeiGene [6][32] Core Insights - The commercial insurance innovative drug list is expected to be released soon, which is anticipated to improve the domestic market significantly [33] - The National Healthcare Security Administration and National Health Commission have released measures to support the high-quality development of innovative drugs, focusing on high-innovation drugs with significant clinical value [33] - The pharmaceutical sector underperformed the market in June 2025, with the Shanghai Composite Index rising by 2.9% while the SW Pharma Bio index rose by only 0.7% [34] - The Hang Seng Healthcare sector outperformed the market with an increase of 8.4% in June 2025, while the U.S. S&P Healthcare Select Sector underperformed with a rise of only 1.9% [35] Summary by Sections - **Investment Highlights**: Continuous positive outlook for innovative drugs and industry chain, with specific A-Shares and H-Shares recommended for investment [32][6] - **Market Performance**: In June 2025, the pharmaceutical sector's performance was weak compared to the overall market, ranking 19th among Shenwan primary industries [34] - **Sub-sector Analysis**: The best-performing sub-sectors included medical services (+4.8%), chemical preparations (+0.8%), and chemical raw materials (+0.5%) [34][20] - **Stock Performance**: Top gainers in the pharmaceutical sector included Zhejiang Anglikang Pharmaceutical (+146.4%) and Hubei Huaqiang High-Tech Co., Ltd. (+67.4%), while top losers included Kexing Biopharm Co., Ltd. (-28.7%) [34][23]

Summary of Conference Call Records Industry Overview - The innovative drug industry chain is gradually stabilizing and recovering, with CXO orders rebounding since last year, leading to strong mid-year performance in key segments [1][2][3] - The overall trend for the pharmaceutical sector in Q2 2025 is positive, particularly in innovative drugs and their supply chains, despite recent market fluctuations [2][3] Key Companies and Performance - **Hengrui, Huadong, and China Biopharmaceutical** are expected to achieve double-digit growth in Q2 and for the entire year [1][6] - **WuXi AppTec** aims for a revenue target of 43 billion, with an expected growth of over 15% and faster net profit growth; **WuXi AppTec's** revenue growth is projected at over 35% for the year [1][11] - **Kelaiying** anticipates a revenue growth of over 15% for the year, while **Kanglong Huacheng** expects around 10% growth in revenue and profit for Q2 [1][11][13] - **BaiPuSi and Haoyuan Pharmaceutical** are performing well, with most companies expecting revenue growth of over 20% [1][15] Market Catalysts - Recent adjustments in medical insurance policies and industry conferences (WCLC, ESMO, Ash) are seen as potential catalysts for growth in the innovative drug sector [1][7][9] - The upcoming medical insurance negotiations and directory adjustments are expected to be significant driving forces in the second half of the year [9][10] Investment Opportunities - Despite a recent decline in market sentiment, large-cap companies like **BaiJi, Hengrui, XinDa, Kangfang, and Shiyao** are recommended for investment, along with smaller companies like **Dizhe and Yifangzejin** [10] - The CXO and upstream sectors are highlighted as key investment areas, with strong performance expected due to improved orders and geopolitical factors [19][20] Sector Performance - The medical device sector is still in a clearing inventory phase, with some companies showing good growth, particularly in overseas markets [17][18] - The OTC and traditional Chinese medicine sectors have not shown significant improvement but may see recovery in the second half of the year [5][18] Future Outlook - The overall outlook for the second half of 2025 remains optimistic, with expectations of continued growth in the innovative drug sector and supportive external factors [9][24] - The domestic financing environment is expected to improve, with a notable increase in activity anticipated in the latter half of the year [26][38] Conclusion - The innovative drug industry chain, particularly the CXO segment, is positioned for strong growth, supported by favorable market conditions and strategic company performances. Investors are encouraged to focus on key players within this sector for potential opportunities.

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a net value increase of 1.77% recently and a year-to-date return of 8.30% [1] - The fund's recent one-month return is 0.30%, with a six-month return of 8.30%, ranking 628 out of 1722 in its category for both periods [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and has a total scale of 15.613 billion yuan as of March 31, 2025 [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at various financial institutions [2]

Group 1 - The CRO concept stocks experienced a partial surge, with Lingkang Pharmaceutical (603669) hitting the daily limit up [1] - Baicheng Pharmaceutical (301096), Kangpeng Technology, Zhaoyan New Drug (603127), and Kailaiying (002821) also saw increases [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry, indicating a positive outlook for the sector compared to the overall market performance [23]. Core Insights - The pharmaceutical sector experienced a decline of 4.4% this week, underperforming the Shanghai Composite Index, which fell by 0.5% [2][3]. - The overall valuation of the pharmaceutical sector stands at 28.7 times PE (2025E), ranking it 5th among 31 sub-industries [5][10]. - Recent policies from the National Medical Products Administration (NMPA) aim to support the development of high-end medical devices and accelerate the clinical review process for innovative drugs [12]. - Shengnuo Biopharma forecasts a significant profit increase for H1 2025, with expected net profit ranging from 77.03 million to 94.14 million yuan, marking a year-on-year growth of 253.54% to 332.10% [13]. Market Performance - The pharmaceutical and biotechnology index ranked 29th out of 31 sub-industries this week, with various segments showing declines, including chemical preparations (-5.7%) and medical devices (-3.7%) [2][5]. - The report highlights the strong growth in product revenue and licensing deals in the innovative drug sector over the past three years, with a focus on companies expected to release major products and those involved in the CXO industry [12]. Key Events - The NMPA has approved measures to encourage the innovation of high-end medical devices, including optimizing special approval processes and enhancing regulatory frameworks [12]. - The NMPA has also proposed a 30-day review process for clinical trial applications of innovative drugs, aimed at improving the efficiency of drug development [12].

一、股东大会审议通过权益分派方案情况 度权益分派方案。具体方案为：以分配方案未来实施时股权登记日享有利润分配 权的股本总额为基数，拟向全体股东每 10 股派发现金股利人民币 11 元（含税）， 不送红股，不以资本公积金转增股本。公司剩余未分配利润留待以后年度分配。 本次利润分配方案实施时，如因新增股份上市、股份回购、库存股完成股权激励 过户、回购注销等原因使得享有利润分配权的股份总额发生变动，公司将按照分 配比例固定的原则对分配总金额进行相应调整。 股变更为 333,040,460 股，系公司回购注销 2020 年限制性股票激励计划预留授 予离职激励对象 1,680 股股份所致，具体内容详见公司 2025 年 5 月 27 日刊登于 《中国证券报》、 证券代码：002821 证券简称：凯莱英 公告编号：2025-037 凯莱英医药集团（天津）股份有限公司 关于 2024 年年度权益分派实施的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 特别提示 权益分派方案已获公司2024年度股东大会审议通过。本次可参与利润分配的A股 总股本为331,597,760股（以 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-037 凯莱英医药集团（天津）股份有限公司 特别提示 1、凯莱英医药集团（天津）股份有限公司（以下简称"公司"）2024年度 权益分派方案已获公司2024年度股东大会审议通过。本次可参与利润分配的A股 总股本为331,597,760股（以公司目前A股总股本333,040,460为基数，扣除公司 回购专用账户中的回购股份总数1,442,700股）,公司本次A股现金分红共计 364,757,536.00元（含税）。 2、因公司回购账户股份不参与分红，本次权益分派实施后，根据股票市值 不变原则，实施权益分派前后公司A股总股本保持不变，现金分红总额分摊到每 一股的比例将减小。本次权益分派按公司总股本折算的每股现金红利为 1.0952349元/股（计算结果直接截取小数点后七位，不四舍五入）。本次权益分 派实施后的除权除息参考价=除权除息日前一交易日收盘价-按公司总股本折算 每股现金分红金额=股权登记日收盘价-1.0952349元/股。 一、股东大会审议通过权益分派方案情况 1、2025 年 6 月 11 日公司召开 2024 年度股东大会，审议通过了 202 ...

Group 1 - The CRO concept sector experienced a decline of 1.65%, ranking among the top declines in the concept sector, with notable declines from companies such as Saint Noble Bio, Meinohua, and Ruizhi Medicine [1][2] - Among the CRO concept stocks, 10 stocks saw price increases, with Wanbang Pharmaceutical, Puni Testing, and Huace Testing leading the gains at 6.96%, 3.37%, and 2.25% respectively [1][2] - The CRO concept sector faced a net outflow of 1.109 billion yuan in main funds, with 48 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2][3] Group 2 - The top net outflow stock was WuXi AppTec, with a net outflow of 337 million yuan, followed by Lianhua Technology, Ruizhi Medicine, and Kailai Ying with net outflows of 136 million yuan, 105 million yuan, and 86 million yuan respectively [2][3] - The stocks with the highest net inflow included Huace Testing, Dongcheng Pharmaceutical, and Jinshi Yao, with net inflows of 29.24 million yuan, 23.51 million yuan, and 15.25 million yuan respectively [2][4] - The overall market sentiment reflected a mixed performance across various concept sectors, with brain-computer interface leading the gains at 6.63% while the CRO concept lagged behind [2][4]

证券代码：002821 证券简称：凯莱英 公告编号：2025-036 凯莱英医药集团（天津）股份有限公司 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开与出席情况 （一）会议召开情况 网络投票时间：2025年6月11日（周三），其中，通过深圳证券交易所交易 系统进行网络投票的时间为2025年6月11日上午9：15-9：25，9：30-11：30，下 午13:00-15:00；通过深圳证券交易所互联网投票系统投票的时间为2025年6月11 日上午9:15至2025年6月11日下午15:00期间的任意时间。 及《公司章程》的有关规定。 （二）会议出席情况 （1）2024年度股东大会出席情况 其中：A股股东人数 518 境外上市外资股股东人数（H股） 2 其中：A股股东持有股份总数（股） 184,262,000 境外上市外资股股东持有股份总数（H股） 7,706,059 份总数的比例 其中：A股股东持股占有表决权股份总数的比例 52.4016% 境外上市外资股股东持股占有表决权股份总数的比例 2.1915% 注1：通过现场投票的A股股东7人，代 ...

证券代码：002821 证券简称：凯莱英 公告编号：2025-036 凯莱英医药集团（天津）股份有限公司 2024 年度股东大会、2025 年第二次 A 股类别股东大会及 特别提示： 1、本次股东大会没有出现议案被否决的情形； 2、本次股东大会没有涉及变更前次股东大会决议的情形； 3、本次股东大会以现场投票与网络投票相结合的方式召开。 一、会议召开与出席情况 （一）会议召开情况 1、 现场会议召开时间：2025年6月11日（周三）下午14:00 网络投票时间：2025年6月11日（周三），其中，通过深圳证券交易所交易 系统进行网络投票的时间为2025年6月11日上午9：15-9：25，9：30-11：30，下 午13:00-15:00；通过深圳证券交易所互联网投票系统投票的时间为2025年6月11 日上午9:15至2025年6月11日下午15:00期间的任意时间。 2、会议召开地点：天津经济技术开发区第七大街71号公司会议室 2025 年第二次 H 股类别股东大会决议公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 3、会议召开方式：现场投票和网络投票相结合方 ...